Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 10
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Bauer, M Berman, S Stamm, T Plotkin, M Adli, M Pilhatsch, M London, E D Hellemann, G S Whybrow, P C and Schlagenhauf, F 2016. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. Molecular Psychiatry, Vol. 21, Issue. 2, p. 229.


    Suppes, Trisha Kroger, Hans Pikalov, Andrei and Loebel, Antony 2016. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. Journal of Psychiatric Research, Vol. 78, p. 86.


    Citraro, Rita Leo, Antonio De Fazio, Pasquale De Sarro, Giovambattista and Russo, Emilio 2015. Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy. British Journal of Pharmacology, Vol. 172, Issue. 12, p. 3177.


    Godman, Brian 2015. The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine. Journal of Medical Economics, Vol. 18, Issue. 11, p. 871.


    Loebel, Antony Xu, Jane Hsu, Jay Cucchiaro, Josephine and Pikalov, Andrei 2015. The development of lurasidone for bipolar depression. Annals of the New York Academy of Sciences, Vol. 1358, Issue. 1, p. 95.


    Malempati, Rao N. 2015. Aripiprazole Adjunct Treatment in Bipolar I or II Disorder, Depressed State. The Journal of Nervous and Mental Disease, Vol. 203, Issue. 1, p. 58.


    Sajatovic, Martha Levin, Jennifer B Sams, Johnny Cassidy, Kristin A Akagi, Kouri Aebi, Michelle E Ramirez, Luis F Safren, Steven A and Tatsuoka, Curtis 2015. Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder. Bipolar Disorders, Vol. 17, Issue. 6, p. 653.


    Fond, G. Hamdani, N. Kapczinski, F. Boukouaci, W. Drancourt, N. Dargel, A. Oliveira, J. Le Guen, E. Marlinge, E. Tamouza, R. and Leboyer, M. 2014. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatrica Scandinavica, Vol. 129, Issue. 3, p. 163.


    Samalin, Ludovic Tremey, Aurore and Llorca, Pierre-Michel 2014. Quetiapine extended release for the treatment of bipolar disorder. Expert Review of Neurotherapeutics, Vol. 14, Issue. 9, p. 987.


    Chen, Wenjia DeVeaugh-Geiss, Angela M. Palmer, Liisa Princic, Nicole and Chen, Ya-Ting 2013. Patterns of atypical antipsychotic therapy use in adults with bipolar I disorder in the USA. Human Psychopharmacology: Clinical and Experimental, Vol. 28, Issue. 5, p. 428.


    ×

A systematic review of the evidence for the treatment of acute depression in bipolar I disorder

  • Michael A. Cerullo (a1) and Stephen M. Strakowski (a1)
  • DOI: http://dx.doi.org/10.1017/S1092852913000102
  • Published online: 18 March 2013
Abstract

In this article, we examined evidence for the acute treatment of depression in bipolar I disorder, focusing on double-blind, placebo-controlled studies with a definite primary outcome measure and published in peer review journals. Quetiapine and olanzapine/fluoxetine are currently approved by the FDA for the treatment of bipolar depression, and a number of additional agents (including other atypical antipsychotics, mood stabilizers, antidepressants, and novel compounds) have been studied with varying degrees of efficacy. The medication with the most evidence for efficacy in bipolar depression is quetiapine, with five studies showing positive efficacy compared to placebo. In contrast, five studies of lamotrigine were negative, although meta-analyses of the pooled have found some treatment effects. Two studies of olanzapine and olanzapine/fluoxetine and three small studies of divalproex showed significant efficacy in treating bipolar depression. Two studies of aripiprazole found no differences compared to placebo. Early research on lithium in bipolar depression had significant methodological flaws, and only one study of lithium met our primary search criteria. To better understand the role of antidepressants, we also examined studies of antidepressants as adjunctive treatment of bipolar depression in participants taking mood stabilizers or atypical antipsychotics. These studies reported mixed results for a variety of antidepressants, but the majority found no differences compared to placebo. Other studies of adjunctive treatment were also discussed. There has been one positive adjunctive study each of lamotrigine, omega-3 fatty acids, modafinil, and armodafinil, while there was one negative trial each of omega-3 fatty acids, ziprasidone, and levetiracetam.

Copyright
Corresponding author
*Address for correspondence: Michael Cerullo, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati COM, 260 Stetson Street, Suite 3200, Cincinnati, OH 45219-0516, USA. Email Michael.Cerullo@uc.edu)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.W Narrow , D Rae , L Robins , etal. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys’ estimates. Arch Gen Psychiatry. 2002; 59: 115123.

2.L Judd , H Akiskal . The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003; 73: 123131.

3.G Zornberg , H Pope . Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol. 1993; 13(6): 397408.

4.RJ Van Lieshout , GM MacQueen . Efficacy and acceptability of mood stabilizers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry. 2010; 196: 266273.

5.AM Nivoli , F Colom , A Murru , etal. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord. 2011; 129: 1426.

6.E Vieta , J Locklear , O Gunther , etal. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol. 2010; 30(5): 579590.

7.JR Geddes , JR Calabrese , GM Goodwin . Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry. 2009; 194: 49.

8.F De Fruyt , E Deschepper , K Audenaert , etal. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2011; 26(5): 603617.

9.LA Smith , VR Cornelius , JM Azorin , etal. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord. 2010; 122: 19.

10.DJ Bond , RW Lam , LN Yatham . Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord. 2010; 124: 228234.

11.KN Fountoulakis , H Grunze , P Panagiotidis , G Kaprinis . Treatment of bipolar depression: an update. J Affect Disord. 2008; 109: 2134.

13.MM Sidor , GM MacQueen . Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011; 72(2): 156167.

14.H Gijsman , J Geddes , J Rendell , W Nolen , G Goodwin . Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004; 161(9): 15371547.

15.L Spanemberg , R Massuda , L Lovato , etal. Pharmacological treatment of bipolar depression: qualitative systematic review of double-blind randomized clinical trials. Psychiatr Q. 2012; 83: 161175.

16.JR Calabrese , PE Keck , W Macfadden , etal. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162(7): 13511360.

17.ME Thase , W Macfadden , RH Weisler , etal. Efficacy of quetiapine monotherapy in bipolar I and II depression. J Clin Psychopharmacol. 2006; 26(6): 600609.

18.S McElroy , R Weisler , W Chang , etal. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010; 71(2): 163174.

19.T Suppes , C Datto , M Minkwitz , etal. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010; 121: 106115.

20.AH Young , FRCPsychSL McElroy , etal. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010; 71(2): 150162.

21.M Tohen , E Vieta , J Calabrese , etal. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003; 60: 10791088.

23.ME Thase , A Jonas , A Khan , etal. Aripiprazole monotherapy in non-psychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008; 28(1): 1320.

24.L Lombardo , G Sachs , S Kolluri , C Kremer , R Yang . Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression. J Clin Psychopharmacol. 2012; 32(4): 470478.

25.GS Sachs , KS Ice , PB Chappell . Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011; 72(10): 14131422.

26.JR Calabrese , RF Huffman , RL White , etal. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008; 10: 323333.

27.JR Calabrese , CL Bowden , GS Sachs , etal. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I disorder. J Clin Psychiatry. 1999; 60(2): 7988.

28.ML van der Loos , PG Mulder , EG Hartong , etal. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(2): 223231.

29.EB Brown , SL McElroy , PE Keck , etal. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 206; 67: 10251033.

30.LL Davis , A Bartolucci , F Petty . Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005; 85: 259266.

31.SN Ghaemi , WS Gilmer , JF Goldberg , etal. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry. 2007; 68(12): 18401844.

32.DJ Muzina , K Gao , DE Kemp . Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naïve bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011; 72(6): 813819.

33.MB Baron , ES Gershon , V Rudy , etal. Lithium carbonate response in depression. Arch Gen Psychiatry. 1975; 32: 11071111.

34.FK Goodwin , DL Murphy , WE Bunney . Lithium-carbonate treatment in depression and mania. Arch Gen Psychiatry. 1969; 21: 486496.

35.R Noyes , GM Dempsey , A Blum , GL Cavanaugh . Lithium treatment of depression. Compr Psychiatry. 1974; 15(3): 187193.

37.FK Goodwin , DL Murphy , DL Dunner , WE Bunney . Lithium response in unipolar versus bipolar depression. Am J Psychiatry. 1972; 129(1): 7679.

38.JB Cohn , G Collins , E Ashbrook , JF Wernicke . A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989; 4: 313322.

39.CB Nemeroff , DL Evans , L Gyulai , etal. Double-blind, placebo controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001; 158(6): 906912.

40.GS Sachs , AA Nierenberg , JR Calabrese , etal. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007; 356(17): 17111722.

41.JR Calabrese , TA Ketter , JM Youakim , etal. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010; 71(10): 13631370.

42.A Saricicek , K Maloney , A Muralidharan , etal. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011; 72(6): 744750.

43.SN Ghaemi , FK Goodwin . Antidepressants for bipolar depression. Am J Psychiatry. 2005; 162(8): 15451546.

44.JF Goldberg , CJ Truman . Antidepressant-induced mania: an overview of current controversies. Bipolar Disord. 2003; 5: 407420.

45.L Tondo , G Vazquez , RJ Baldessarini . Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010; 121: 404414.

46.RW Licht , H Gijsman , WA Nolen , J Angst . Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand. 2008; 118: 337346.

47.MA Frye , H Grunze , T Suppes , etal. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007; 164: 12421249.

48.AL Stoll , WE Severus , MP Freeman , etal. Omega 3 fatty acids in bipolar disorder. Arch Gen Psychiatry. 1999; 56: 407412.

49.PE Keck , J Mintz , SL McElroy , etal. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. 2006; 60: 10201022.

50.LL Altshuler , RM Post , G Hellemann , etal. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded randomized study. J Clin Psychiatry. 2009; 70(4): 450457.

51.SN Ghaemi , MM Ostacher , RS El-Mallakh , etal. Antidepressant discontinuation in bipolar depression: a systematic treatment enhancement program for bipolar disorder (STEP-BP) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010; 71(4): 372380.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: